Forbes J M & Co. LLP Buys 312 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Forbes J M & Co. LLP boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 150.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 519 shares of the biopharmaceutical company’s stock after purchasing an additional 312 shares during the period. Forbes J M & Co. LLP’s holdings in Regeneron Pharmaceuticals were worth $370,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of REGN. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals in the third quarter worth about $37,000. Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $39,000. Finally, Valley Wealth Managers Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $49,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 1.7 %

Regeneron Pharmaceuticals stock opened at $710.00 on Friday. The firm has a market cap of $78.02 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73. The firm has a 50 day moving average price of $715.81 and a two-hundred day moving average price of $911.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the business earned $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th.

Wall Street Analyst Weigh In

REGN has been the topic of several analyst reports. Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Finally, Bank of America reaffirmed an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.